Melanoma & Skin Cancer | Specialty

VP-315 Induces Reductions in Tumor Size in Basal Cell Carcinoma

August 14th 2024

Treatment with VP-315 led to reductions in tumor size in patients with basal cell carcinoma.

Dr Long on Unmet Needs in BRAF-Mutant Melanoma

August 14th 2024

Georgina Long, MBBS, PhD, FRACP, discusses unmet needs for BRAF-mutant melanoma, highlighting key insights from the phase 3 NADINA trial.

Toripalimab sNDA Under Review in China for Frontline Unresectable or Metastatic Melanoma

August 13th 2024

A sNDA seeking the approval of toripalimab for frontline use in patients with unresectable or metastatic melanoma is under review by the NMPA.

Tumor-Informed ctDNA Assay May Aid Surveillance Strategies in Merkel Cell Carcinoma

August 5th 2024

A tumor-informed ctDNA assay showed high sensitivity and specificity as well as potential for ctDNA to be used as a prognostic biomarker during surveillance in Merkel cell carcinoma.

Integrated 15-GEP and PRAME Classifier Shows Prognostic Accuracy in Uveal Melanoma

August 1st 2024

Integrating 15-GEP with PRAME expression status into a 4-group prognostic classification system showed prognostic accuracy in uveal melanoma.

BNT111 Plus Cemiplimab Generates Responses in Unresectable Stage III/IV Melanoma

July 30th 2024

The addition of BNT111 to cemiplimab has produced clinical activity in anti-PD-(L)1 relapsed/refractory unresectable stage III or IV melanoma.

FDA Accepts Resubmission of BLA for Cosibelimab in Locally Advanced or Metastatic CSCC

July 25th 2024

The FDA has accepted the resubmission of a BLA for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma

July 16th 2024

Adjuvant nivolumab plus ipilimumab significantly improved 3-year DMFS rates compared with historical controls in patients with high-risk uveal melanoma.

Neoadjuvant Cemiplimab Underscores Push to Bolster Treatment of CSCC

July 10th 2024

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab for the treatment of cutaneous squamous cell carcinoma.

OBX-115 Earns FDA Fast Track Designation for Advanced Melanoma

July 9th 2024

The FDA has granted fast track designation to OBX-115 for advanced melanoma that is refractory to or relapsed after immune checkpoint inhibitors.

Dr Khushalani on Fixed-Dose Treatment Regimens in Advanced Melanoma

July 2nd 2024

Nikhil Khushalani, MD, discusses the benefits and limitations of fixed-dose treatment regimens in patients with unresectable or metastatic melanoma.

FDA Receives BLA Resubmission for Cosibelimab in Advanced CSCC

July 2nd 2024

The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.

Dr Hauschild on the Role of Adjuvant/Neoadjuvant Therapy in Melanoma Management

June 25th 2024

Axel Hauschild, MD, PhD, discusses the role of adjuvant and neoadjuvant therapy in melanoma, highlighting the utility of perioperative approaches.

Dr Tarhini on the Utility of a Prognostic Model in Advanced Melanoma Following ICI Treatment

June 24th 2024

Ahmad Tarhini, MD, PhD, discusses a prognostic model evaluating patients with advanced melanoma treated with immune checkpoint inhibitors.

Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 Years

June 17th 2024

A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.

Long-Term Follow up for Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutated Melanoma: Final Results of the COMBI-AD Study

June 17th 2024

COMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.

Phase 3 Study (PIVOTAL) of Neoadjuvant Intralesional Daromun vs. Immediate Surgery in Fully Resectable Melanoma With Regional Skin and/or Nodal Metastases

June 17th 2024

PIVOTAL (NCT02938299) is an open label, randomized, multicenter, phase 3 trial evaluating Daromun as a neoadjuvant intralesional therapy for resectable, locally advanced Stage III melanoma.

Recent Advances in the Evolving Treatment Landscape of Melanoma

June 14th 2024

UV1 Cancer Vaccine as a Pembrolizumab Add-On Continues to Strengthen OS in Melanoma

June 11th 2024

UV1 added to pembrolizumab elicited sustained OS outcomes as frontline therapy in advanced, unresectable, or metastatic malignant melanoma.

New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings

June 6th 2024

The combination of RP1 and nivolumab was safe and effective in patients with anti–PD-1-failed advanced melanoma.